Veeva Systems Inc. provides cloud-based software for the life sciences industry in North America, Europe, Asia Pacific, the Middle East, Africa, and Latin America. The company is headquartered in Pleasanton, California.
| Revenue (TTM) | $3.46B |
| Gross Profit (TTM) | $2.59B |
| EBITDA | $1.08B |
| Operating Margin | 29.60% |
| Return on Equity | 14.40% |
| Return on Assets | 7.58% |
| Revenue/Share (TTM) | $21.15 |
| Book Value | $45.92 |
| Price-to-Book | 6.76 |
| Price-to-Sales (TTM) | 14.22 |
| EV/Revenue | 12.47 |
| EV/EBITDA | 40.10 |
| Quarterly Earnings Growth (YoY) | 39.50% |
| Quarterly Revenue Growth (YoY) | 17.60% |
| Shares Outstanding | $161.91M |
| Float | $148.28M |
| % Insiders | 8.62% |
| % Institutions | 92.58% |
Volatility is currently contracting
Investors with an interest in Medical Info Systems stocks have likely encountered both Omnicell (OMCL) and Veeva Systems (VEEV). But which of these two companies is the best option for those looking for undervalued stocks?
Agentic CRM platform to drive unified engagement worldwide PLEASANTON, Calif., Nov. 4, 2026 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced that UCB has committed to Veeva Vault CRM, the agentic engagement platform for life sciences.
Veeva System earns a Buy rating, justified by re-accelerating revenue growth, rare 45% operating margins, and sticky regulated software. VEEV trades at a 70% P/E premium to the sector but below its five-year average, with a PEG of 0.97x versus the sector median of 1.87x. Recent strategic wins include 14 of the top 20 biopharma CRM commitments and IQVIA standardizing on Veeva's clinical applications.
Veeva Systems earns a buy rating as core business growth re-accelerates, with AI-driven upside from Falcon agents not yet priced in. Commercial Solutions segment re-accelerated to 13% YoY subscription growth; R&D and Quality remain robust at 19.3% YoY, both supporting the investment thesis. Major tailwinds include CRM migration from Salesforce, early-stage AI adoption, and resilient end-markets in highly regulated life sciences.
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
Veeva Systems has rebounded strongly, outperforming prior valuation estimates as fundamentals and growth accelerate. VEEV reported FQ2 FY27 revenue of $928M, up 18% Y/Y, and GAAP operating income up 40% Y/Y, exceeding previous growth assumptions. The company achieved 70% retention of its biopharma CRM subscription base, securing all four previously undecided top-20 accounts.
Veeva Systems, Inc. (VEEV) shares are up 1,062% since institutions first bought big in 2015.
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
Zacks.com users have recently been watching Veeva (VEEV) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
PLEASANTON, Calif., Oct. 14, 2026 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) will host its investor day virtually on Thursday, November 5, 2026.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on VEEV and any ticker you trade — then tracks every position and per-strategy win rate.
